| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$24,511,741 |
|
|
|
Indirect Value
|
$3,299,393 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$27,811,135 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-05-15 |
55,325 |
2024-05-15 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
193 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
OE |
$91.05 |
$392,517 |
D/D |
4,311 |
37,727 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2019-02-04 |
4 |
AS |
$186.52 |
$2,377,296 |
D/D |
(12,722) |
38,037 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2014-02-05 |
4 |
A |
$0.01 |
$119 |
D/D |
11,875 |
38,436 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2014-06-24 |
4 |
AS |
$98.03 |
$4,141,768 |
D/D |
(42,250) |
38,671 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2014-09-30 |
4 |
AS |
$111.33 |
$9,690,570 |
D/D |
(86,000) |
38,671 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Policy, Access & Value |
• – – |
2014-10-28 |
4 |
AS |
$115.00 |
$1,380,000 |
D/D |
(12,000) |
38,671 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-07-25 |
4 |
AS |
$49.66 |
$74,882 |
D/D |
(1,500) |
39,074 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-19 |
4 |
AS |
$157.67 |
$5,125,400 |
D/D |
(32,422) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-22 |
4 |
AS |
$160.00 |
$2,200,000 |
D/D |
(13,750) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-23 |
4 |
AS |
$165.00 |
$960,960 |
D/D |
(5,824) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-29 |
4 |
AS |
$170.00 |
$2,564,450 |
D/D |
(15,085) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-02-05 |
4 |
AS |
$158.55 |
$736,800 |
D/D |
(4,520) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-18 |
4 |
AS |
$242.04 |
$849,780 |
D/D |
(3,489) |
39,447 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-01-11 |
4 |
AS |
$37.66 |
$16,985 |
D/D |
(451) |
39,838 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-02-25 |
4 |
AS |
$211.56 |
$765,307 |
D/D |
(3,586) |
40,133 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-04-27 |
4 |
AS |
$215.58 |
$839,193 |
D/D |
(3,884) |
40,133 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-05-17 |
4 |
AS |
$215.59 |
$9,736 |
D/D |
(45) |
40,133 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-02-28 |
4 |
AS |
$45.00 |
$726,830 |
D/D |
(15,887) |
40,154 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2011-03-03 |
4 |
AS |
$49.50 |
$471,785 |
D/D |
(9,531) |
40,154 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2010-10-28 |
4 |
AS |
$38.50 |
$182,875 |
D/D |
(4,750) |
40,160 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2019-02-11 |
4 |
AS |
$179.44 |
$6,319,216 |
D/D |
(35,095) |
40,165 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$364,239 |
D/D |
4,097 |
40,287 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2009-02-05 |
4 |
A |
$0.01 |
$122 |
D/D |
12,200 |
40,366 |
0 |
- |
|
193 Records found
|
|
Page 3 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
